Part D not immune to fraud
Identifying fraud in the Medicare prescription drug program may be difficult relative to other government programs due to a lack of transparency in the market, witnesses at a House Committee on Oversight and Government Reform hearing on pharmaceutical waste, fraud and abuse suggest. The Feb. 9 hearing also addresses fraud and abuse related to Medicaid pricing and the 340B program. Waxman indicates that issues such as the susceptibility of Part D to fraud and the limitations of enforcement efforts to effectively litigate violations will be an integral part of the committee's investigative priorities for the next two years...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.